JP2014505658A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014505658A5 JP2014505658A5 JP2013537854A JP2013537854A JP2014505658A5 JP 2014505658 A5 JP2014505658 A5 JP 2014505658A5 JP 2013537854 A JP2013537854 A JP 2013537854A JP 2013537854 A JP2013537854 A JP 2013537854A JP 2014505658 A5 JP2014505658 A5 JP 2014505658A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- ras
- mutation
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 52
- 102000016914 ras Proteins Human genes 0.000 claims 19
- 108010014186 ras Proteins Proteins 0.000 claims 19
- 230000035772 mutation Effects 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 13
- 239000012453 solvate Substances 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 9
- 229940125431 BRAF inhibitor Drugs 0.000 claims 6
- 210000001185 bone marrow Anatomy 0.000 claims 6
- 208000032839 leukemia Diseases 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 210000004881 tumor cell Anatomy 0.000 claims 5
- 229940124647 MEK inhibitor Drugs 0.000 claims 4
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 4
- 101710113436 GTPase KRas Proteins 0.000 claims 3
- 102100039788 GTPase NRas Human genes 0.000 claims 3
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 210000003969 blast cell Anatomy 0.000 claims 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 3
- 102200006537 rs121913529 Human genes 0.000 claims 3
- 102200006541 rs121913530 Human genes 0.000 claims 3
- 229960002930 sirolimus Drugs 0.000 claims 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 229960005167 everolimus Drugs 0.000 claims 2
- 229940124302 mTOR inhibitor Drugs 0.000 claims 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 2
- 102200006562 rs104894231 Human genes 0.000 claims 2
- 102200006532 rs112445441 Human genes 0.000 claims 2
- 102220197780 rs121434596 Human genes 0.000 claims 2
- 102200006525 rs121913240 Human genes 0.000 claims 2
- 102200006531 rs121913529 Human genes 0.000 claims 2
- 102200006539 rs121913529 Human genes 0.000 claims 2
- 102200006538 rs121913530 Human genes 0.000 claims 2
- 102200006540 rs121913530 Human genes 0.000 claims 2
- 102200006533 rs121913535 Human genes 0.000 claims 2
- 102200155721 rs121918464 Human genes 0.000 claims 2
- 102220056962 rs121918464 Human genes 0.000 claims 2
- 102200155722 rs121918465 Human genes 0.000 claims 2
- 102200007373 rs17851045 Human genes 0.000 claims 2
- 102200097053 rs199473666 Human genes 0.000 claims 2
- 102200124922 rs267606920 Human genes 0.000 claims 2
- 102200006648 rs28933406 Human genes 0.000 claims 2
- 229960000235 temsirolimus Drugs 0.000 claims 2
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 108020004705 Codon Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 206010024291 Leukaemias acute myeloid Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 206010028561 Myeloid metaplasia Diseases 0.000 claims 1
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 claims 1
- 229960002938 bexarotene Drugs 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 1
- -1 dehololimus Chemical compound 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000003205 genotyping method Methods 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 102200006534 rs104894365 Human genes 0.000 claims 1
- 102200055464 rs113488022 Human genes 0.000 claims 1
- 102200014493 rs121909124 Human genes 0.000 claims 1
- 102220197819 rs121913227 Human genes 0.000 claims 1
- 102220197820 rs121913227 Human genes 0.000 claims 1
- 102220197823 rs121913338 Human genes 0.000 claims 1
- 102200055449 rs121913341 Human genes 0.000 claims 1
- 102200055517 rs121913348 Human genes 0.000 claims 1
- 102200055523 rs121913348 Human genes 0.000 claims 1
- 102200055529 rs121913351 Human genes 0.000 claims 1
- 102200055532 rs121913355 Human genes 0.000 claims 1
- 102200055451 rs121913361 Human genes 0.000 claims 1
- 102200055461 rs121913366 Human genes 0.000 claims 1
- 102200055463 rs121913369 Human genes 0.000 claims 1
- 102220010949 rs121913375 Human genes 0.000 claims 1
- 102200055469 rs121913377 Human genes 0.000 claims 1
- 102200055501 rs180177032 Human genes 0.000 claims 1
- 102200055521 rs180177033 Human genes 0.000 claims 1
- 102200001486 rs397514547 Human genes 0.000 claims 1
- 102200031604 rs750730042 Human genes 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41056010P | 2010-11-05 | 2010-11-05 | |
| US61/410,560 | 2010-11-05 | ||
| US42271510P | 2010-12-14 | 2010-12-14 | |
| US61/422,715 | 2010-12-14 | ||
| PCT/US2011/059285 WO2012061683A2 (en) | 2010-11-05 | 2011-11-04 | Methods for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014505658A JP2014505658A (ja) | 2014-03-06 |
| JP2014505658A5 true JP2014505658A5 (enExample) | 2014-12-18 |
Family
ID=46025128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013537854A Pending JP2014505658A (ja) | 2010-11-05 | 2011-11-04 | 癌を治療する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20130217710A1 (enExample) |
| EP (1) | EP2635286A4 (enExample) |
| JP (1) | JP2014505658A (enExample) |
| WO (1) | WO2012061683A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012068339A2 (en) * | 2010-11-17 | 2012-05-24 | Glaxosmithkline Llc | Methods of treating cancer |
| HK1206611A1 (en) * | 2012-05-31 | 2016-01-15 | Bayer Pharma Aktiengesellschaft | Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients |
| CA2879252C (en) | 2012-08-17 | 2017-10-10 | F. Hoffmann-La Roche Ag | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
| BR112015016559A2 (pt) * | 2013-01-09 | 2017-07-11 | Glaxosmithkline Ip No 2 Ltd | combinação |
| US20160058751A1 (en) * | 2013-03-28 | 2016-03-03 | Cellworks Group, Inc. | Composition and method for treating cancer |
| US9572828B2 (en) * | 2013-07-18 | 2017-02-21 | The Board Of Regents Of The University Of Texas System | Treatment for melanoma |
| WO2015059677A1 (en) * | 2013-10-26 | 2015-04-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Methods of treating cancer |
| WO2015066439A2 (en) * | 2013-11-01 | 2015-05-07 | Foundation Medicine, Inc. | Methods of treating hematological malignancies |
| CN107148481A (zh) | 2014-07-14 | 2017-09-08 | 苏黎世大学医学与自然科学院 | 用于确定患有braf‑阳性癌症的患者为braf抑制剂非响应者且为mapk/erk抑制剂响应者的工具和方法 |
| BR112020020307A2 (pt) | 2018-04-04 | 2021-01-12 | Arvinas Operations, Inc. | Moduladores de proteólise e métodos de uso associados |
| TW202015719A (zh) | 2018-06-19 | 2020-05-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
| MX2022013430A (es) * | 2020-04-27 | 2022-11-14 | Verastem Inc | Metodos para tratar el crecimiento celular anormal. |
| CN115896025B (zh) * | 2021-08-20 | 2025-08-26 | 合肥中科普瑞昇生物医药科技有限公司 | 人原代急性髓系白血病细胞的培养基及培养方法 |
| JPWO2023145530A1 (enExample) * | 2022-01-27 | 2023-08-03 | ||
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| KR20250151412A (ko) | 2023-01-26 | 2025-10-21 | 아비나스 오퍼레이션스, 인코포레이티드 | 세레블론계 kras 분해 단백질 및 이와 관련된 용도 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004004644A2 (en) * | 2002-07-05 | 2004-01-15 | Beth Israel Deaconess Medical Center | Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
| DE602005004286T2 (de) * | 2004-06-11 | 2009-01-02 | Japan Tobacco Inc. | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyridoä2,3-düpyrimidinderivate und verwandte verbindungen zur behandlung von krebs |
| US20060079494A1 (en) * | 2004-09-27 | 2006-04-13 | Santi Daniel V | Specific kinase inhibitors |
| WO2009018238A1 (en) * | 2007-07-30 | 2009-02-05 | Ardea Biosciences, Inc. | Combinations of mek inhibitors and raf kinase inhibitors and uses thereof |
| UA103319C2 (en) * | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| MX336723B (es) * | 2008-07-11 | 2016-01-28 | Novartis Ag | Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek. |
| ES2527625T3 (es) * | 2009-09-23 | 2015-01-27 | Glaxosmithkline Llc | Combinación farmacéutica |
| AU2010306653B2 (en) * | 2009-10-16 | 2013-10-24 | Novartis Ag | Combination |
-
2011
- 2011-11-04 WO PCT/US2011/059285 patent/WO2012061683A2/en not_active Ceased
- 2011-11-04 EP EP11838858.6A patent/EP2635286A4/en not_active Withdrawn
- 2011-11-04 US US13/883,374 patent/US20130217710A1/en not_active Abandoned
- 2011-11-04 JP JP2013537854A patent/JP2014505658A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014505658A5 (enExample) | ||
| Bedard et al. | A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors | |
| Bennouna et al. | Vinflunine: a new microtubule inhibitor agent | |
| Staudacher et al. | Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience | |
| Ikeda et al. | Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine | |
| Colombo et al. | Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial | |
| Koyama et al. | Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase Ib/II study | |
| JP2022082565A (ja) | がんを処置するための方法 | |
| Zhang et al. | Sintilimab for the treatment of non-small cell lung cancer | |
| Yoo et al. | Multicenter phase II study of oxaliplatin, irinotecan, and S-1 as first-line treatment for patients with recurrent or metastatic biliary tract cancer | |
| Yhim et al. | Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): An open-label phase I/II trial | |
| Awad et al. | Radiation recall pneumonitis induced by erlotinib after palliative thoracic radiotherapy for lung cancer: Case report and literature review | |
| Scott et al. | Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma | |
| TWI806822B (zh) | 製備治療癌症之醫藥組成物之用途 | |
| AU2019350581A1 (en) | Methods of treatment of cancer comprising Cdc7 inhibitors | |
| Fricke et al. | Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case report | |
| Kemps et al. | Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium | |
| Saltos et al. | Breaking the impasse: advances in treatment of small cell lung cancer | |
| Devarakonda et al. | Clinical applications of The Cancer Genome Atlas project (TCGA) for squamous cell lung carcinoma | |
| Xiu et al. | Case report: outcome of osimertinib treatment in lung adenocarcinoma patients with acquired KRAS mutations | |
| Bosch-Barrera et al. | ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer | |
| Cheepsattayakorn et al. | Lung cancer chemotherapy, new treatment and related patents | |
| Fu et al. | Case report: A golden tail of immunotherapy: significant tail effect in a chemotherapy-resistant advanced pulmonary sarcomatoid carcinoma patient treated by Sintilimab combined with Anlotinib | |
| Takano et al. | UGT1A1 genotype-specific phase I and pharmacokinetic study for combination chemotherapy with irinotecan and cisplatin: a Saitama Tumor Board study. | |
| CN119156216A (zh) | 尼拉帕尼用于治疗脑癌的用途 |